Ramenani Hari Babu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ramenani Hari Babu has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Anasuya Patil
Department of Pharmaceutics II Block Rajajinagar KLE College of Pharmacy Bengaluru
2 shared publications - Manish Ramesh Bhise
Department of Pharmaceutics, SGSPS, Institute of Pharmacy, Akola (MS), Affiliated to Sant Gadge Baba Amravati University
2 shared publications Abhilasha Gupta
Research Scholar Department of Chemistry School of Basic and Applied Sciences Career Point University Kota
1 shared publicationAnamika Kulshrestha
Department of pharmacology KLE Academy Higher Education and Research Belgavi-590 010 Karnataka India
1 shared publicationJashanjit Singh
Gurukul Institute of Pharmaceutical Sciences Badesh Kalan Khamanon Fatehgarh Sahib Punjab
1 shared publication- Khalid Orayj
King Khalid University, Al Fara, Abha, Saudi Arabia
1 shared publication
Latest Publications
- 16 October 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-2
Comment on “Neurovascular bundle preservation improves postoperative continence recovery in robotic-assisted laparoscopic radical prostatectomy after neoadjuvant hormonal therapy in the treatment of locally advanced prostate cancer: results from a propensity score matched analysis”
- 16 October 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-2
Comment on “Neurovascular bundle preservation improves postoperative continence recovery in robotic-assisted laparoscopic radical prostatectomy after neoadjuvant hormonal therapy in the treatment of locally advanced prostate cancer: results from a propensity score matched analysis”
- 6 October 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (12) , 5659-5660
Comment on "A Randomized-Controlled Trial Examining Telephone-Based Cognitive Behavioral Therapy for Patients After Metabolic and Bariatric Surgery: 18 Month Follow-up Results"
- 6 October 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (12) , 5659-5660
Comment on "A Randomized-Controlled Trial Examining Telephone-Based Cognitive Behavioral Therapy for Patients After Metabolic and Bariatric Surgery: 18 Month Follow-up Results"
- Open Access
- 1 January 2025
- Published by Sakun Publishing House
- Vol. 24 (7s) , 324-334
Formulation And Characterization of a Mucoadhesive Buccal Patch of Glipizide for Sustained Antidiabetic Action
Worldwide, diabetes mellitus is becoming an increasingly serious health concern. Chronically elevated blood sugar levels due to insulin resistance, insulin ineffectiveness, or, more often than not, both, are the root cause of this condition. Significant macrovascular and microvascular consequences, including as cardiovascular disease, neuropathy, nephropathy, and retinopathy, can develop from this metabolic illness if it is not well controlled. These problems greatly diminish quality of life and raise death rates. To effectively treat diabetes, one must take a comprehensive approach that includes medication, physical activity, and dietary changes in order to keep blood glucose levels within a physiological range. The majority of people with Type 2 Diabetes Mellitus (T2DM) rely on oral hypoglycemic agents (OHAs) as their primary medication. Using the solvent casting process, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, carbopol-934P, and Eudragit RL-100 were utilised to create glipizide mucoadhesive buccal films. The films that were prepared were tested for in vitro residence duration, folding endurance, thickness, surface pH, swelling index, in vitro release, and permeation investigations, among other parameters. with consistent drug content. Over the course of more than six hours, the films demonstrated controlled release. Results showed that films containing 5 mg glipizide in a 4.9% w/v hydroxypropylmethylcellulose and 1.5% w/v sodium carboxymethylcellulose solution swelled adequately, had an ideal residence duration, and showed promise for drug release. Researchers determined that the formulation might be used to create buccal films with therapeutic potential.
- 1 January 2025
- Published by Sakun Publishing House
- Vol. 24 (7s) , 324-334
Open AccessFormulation And Characterization of a Mucoadhesive Buccal Patch of Glipizide for Sustained Antidiabetic Action
Worldwide, diabetes mellitus is becoming an increasingly serious health concern. Chronically elevated blood sugar levels due to insulin resistance, insulin ineffectiveness, or, more often than not, both, are the root cause of this condition. Significant macrovascular and microvascular consequences, including as cardiovascular disease, neuropathy, nephropathy, and retinopathy, can develop from this metabolic illness if it is not well controlled. These problems greatly diminish quality of life and raise death rates. To effectively treat diabetes, one must take a comprehensive approach that includes medication, physical activity, and dietary changes in order to keep blood glucose levels within a physiological range. The majority of people with Type 2 Diabetes Mellitus (T2DM) rely on oral hypoglycemic agents (OHAs) as their primary medication. Using the solvent casting process, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, carbopol-934P, and Eudragit RL-100 were utilised to create glipizide mucoadhesive buccal films. The films that were prepared were tested for in vitro residence duration, folding endurance, thickness, surface pH, swelling index, in vitro release, and permeation investigations, among other parameters. with consistent drug content. Over the course of more than six hours, the films demonstrated controlled release. Results showed that films containing 5 mg glipizide in a 4.9% w/v hydroxypropylmethylcellulose and 1.5% w/v sodium carboxymethylcellulose solution swelled adequately, had an ideal residence duration, and showed promise for drug release. Researchers determined that the formulation might be used to create buccal films with therapeutic potential.
- Open Access
- 1 January 2025
- Published by Sakun Publishing House
- Vol. 24 (5s) , 794-801
Design And Development Of Glimepiride Sustained-Release Implants For Long-Term Glycemic Control
Objective: To design and develop sustained-release (SR) glimepiride implants enabling long-term glycemic control with minimized burst release and improved adherence. Methods: Biodegradable PLGA-based in situ forming implants were engineered with solvent-induced phase inversion, using N-methyl-2-pyrrolidone as the primary solvent and polyethylene glycol as a plasticizer to modulate matrix porosity and initial drug efflux. A response-surface design optimized polymer concentration, plasticizer level, and co-solvent ratio to balance burst control and sustained kinetics. Formulations were characterized by SEM, in vitro release profiling over 28 days, and in vivo pharmacokinetics/pharmacodynamics in diabetic rodent models versus oral glimepiride. Results: Increasing PLGA and PEG content reduced surface porosity and attenuated the initial burst while sustaining release, achieving near-zero-order kinetics post-induction. Optimized implants curtailed 2–24h burst and provided depot activity for up to 14 days in vivo, maintaining plasma levels comparable to safe exposures from marketed tablets while prolonging glucose-lowering effects. Embedding glimepiride in nanoparticulate/triblock matrices within PLGA systems further refined release control and depot performance. Design principles and strategies align with contemporary advances in PLGA implant engineering to mitigate burst and enhance completeness of release. Conclusion: Glimepiride SR implants based on optimized PLGA in situ systems offer a feasible depot approach for extended glycemic control, with controlled burst, sustained therapeutic exposure, and potential to improve adherence and outcomes in type 2 diabetes.
- 1 January 2025
- Published by Sakun Publishing House
- Vol. 24 (5s) , 794-801
Open AccessDesign And Development Of Glimepiride Sustained-Release Implants For Long-Term Glycemic Control
Objective: To design and develop sustained-release (SR) glimepiride implants enabling long-term glycemic control with minimized burst release and improved adherence. Methods: Biodegradable PLGA-based in situ forming implants were engineered with solvent-induced phase inversion, using N-methyl-2-pyrrolidone as the primary solvent and polyethylene glycol as a plasticizer to modulate matrix porosity and initial drug efflux. A response-surface design optimized polymer concentration, plasticizer level, and co-solvent ratio to balance burst control and sustained kinetics. Formulations were characterized by SEM, in vitro release profiling over 28 days, and in vivo pharmacokinetics/pharmacodynamics in diabetic rodent models versus oral glimepiride. Results: Increasing PLGA and PEG content reduced surface porosity and attenuated the initial burst while sustaining release, achieving near-zero-order kinetics post-induction. Optimized implants curtailed 2–24h burst and provided depot activity for up to 14 days in vivo, maintaining plasma levels comparable to safe exposures from marketed tablets while prolonging glucose-lowering effects. Embedding glimepiride in nanoparticulate/triblock matrices within PLGA systems further refined release control and depot performance. Design principles and strategies align with contemporary advances in PLGA implant engineering to mitigate burst and enhance completeness of release. Conclusion: Glimepiride SR implants based on optimized PLGA in situ systems offer a feasible depot approach for extended glycemic control, with controlled burst, sustained therapeutic exposure, and potential to improve adherence and outcomes in type 2 diabetes.